In bustling urban centres and quiet rural villages across Nigeria, a silent demographic crisis is unfolding. For most women, the discovery of a breast lump often occurs by accident, typically when the disease has already advanced beyond the window of simple, curable intervention. A stark new report from the African Research Group for Oncology has quantified this failure of preventative care, revealing that a mere 6 per cent of Nigerian women undergo breast cancer screening. This low utilization rate is the primary driver behind the country’s high cancer mortality, as the vast majority of cases are diagnosed at late, often terminal stages.

This statistic is not merely a number it represents a systemic failure of healthcare infrastructure to bridge the gap between diagnosis and survival. While breast cancer stands as the most common malignancy among women in Nigeria, the disconnect between awareness and action is profound. When cases are detected early, survival rates can climb as high as 78 per cent. However, for the roughly 80 per cent of patients who present with advanced stage III or IV disease, the five-year survival rate plummets to a harrowing 33 per cent. For the thousands of families navigating this reality, the 6 per cent figure is the quantitative measure of a preventable national tragedy.

The Anatomy of a Systemic Failure

The low uptake of screening is not born of a lack of medical necessity, but of a broken pathway to care. According to oncology experts, Nigeria currently relies heavily on opportunistic screening—a system where a woman only receives a check-up if she initiates the request or if a healthcare provider happens to suggest it during an unrelated visit. This stands in stark contrast to organized, population-based screening programmes found in high-income nations, which systematically invite women within specific age brackets for mammograms. Without a coordinated national framework to schedule, remind, and subsidize these screenings, the burden remains entirely on the individual.

Furthermore, the economic barriers are formidable. Unlike in several other regional peers where national health insurance schemes have begun to integrate screening, the vast majority of Nigerian patients are forced to navigate the system through out-of-pocket payments. Research indicates that the financial toxicity—the stress of choosing between life-saving diagnostics and daily necessities—often forces women to delay seeking medical attention until pain or disability makes it impossible to ignore. This results in a cycle where late presentation requires more aggressive, expensive treatments, which the healthcare system is often ill-equipped to provide at scale.

A Tale of Two Nations: The East African Contrast

The situation in Nigeria highlights a growing disparity across the African continent. While Nigeria struggles with implementation, Kenya has emerged as a regional leader in cancer control, providing a blueprint that many observers argue is missing in the West African giant. A 2025 assessment by the World Health Organization ranked Kenya at the top of the continent for breast cancer control capacity, citing a score of 66.7 per cent. This success is not accidental it is the result of a deliberate, decade-long investment in health workforce training, robust health information systems, and the implementation of the National Cancer Control Strategy.

• Nigeria: Relies on opportunistic, decentralized screening with no unified national rollout.
• Kenya: Implements a structured, strategic national framework, leading to higher capacity scores.
• Regional Reality: Access to radiotherapy and early diagnostic tools remains highly inequitable, with Nigeria trailing in infrastructure despite high incidence rates.

The disparity between the two nations is further underscored by the availability of high-end diagnostic tools. Kenya is one of the few African nations with widespread access to PET scans, which are vital for staging cancer and tailoring treatment plans. In contrast, even in major Nigerian tertiary hospitals, turnaround times for critical diagnostic pathology and surgery can stretch between one and five months. This delay, compounded by the lack of early screening, ensures that the mortality gap between the two countries remains wide.

The Policy-Reality Gap

The Nigerian government is not unaware of the crisis. The Federal Ministry of Health’s National Cancer Control Plan, spanning 2023 to 2027, explicitly aims to establish a national breast cancer screening programme. Yet, as of the first quarter of 2026, the implementation remains largely in the pilot and planning phases. The challenge lies in moving from policy papers to actual clinical infrastructure on the ground. For the plan to succeed, it must address the shortage of mammography units outside of major cities and train a cadre of community health workers to perform effective clinical breast exams—a low-cost alternative that could revolutionize early detection in rural areas.

For the average citizen, the path forward requires more than just clinical awareness it necessitates a shift in the political economy of health. Without increased federal budgetary allocation for oncology, the reliance on fragmented, private-sector-led screening will ensure that cancer remains a disease of late-stage diagnosis. The African Research Group for Oncology continues to advocate for a multidisciplinary approach, combining surgery, chemotherapy, and significantly improved radiotherapy access. However, none of these therapies can be effective if the patient presents with terminal disease.

Moving Beyond the Statistic

The 6 per cent screening rate is a call to action that can no longer be ignored. Behind this percentage are mothers, sisters, and daughters whose lives are being cut short by a disease that is increasingly treatable when found early. The lessons from across the continent suggest that improved outcomes are possible, but they require a pivot from reactive care to proactive, state-led prevention. As Nigeria navigates its mid-term review of the 2023-2027 health strategy, the question for policymakers is clear: how many more lives must be lost to late diagnosis before the national screening programme moves from a theoretical document to a daily, life-saving reality for women across the country?